These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 8950493)

  • 1. Intracoronary recombinant tissue-type plasminogen activator (rt-PA).
    Tiefenbrunn AJ
    Coron Artery Dis; 1996 Sep; 7(9):637-40. PubMed ID: 8950493
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Experience with low-dose intracoronary recombinant tissue-type plasminogen activator for nonacute total occlusions before percutaneous transluminal coronary angioplasty.
    Ruocco NA; Currier JW; Jacobs AK; Ryan TJ; Faxon DP
    Am J Cardiol; 1991 Dec; 68(17):1609-13. PubMed ID: 1746461
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tissue-type plasminogen activator therapy versus primary coronary angioplasty: impact on myocardial tissue perfusion and regional function 1 month after uncomplicated myocardial infarction.
    Agati L; Voci P; Hickle P; Vizza DC; Autore C; Fedele F; Feinstein SB; Dagianti A
    J Am Coll Cardiol; 1998 Feb; 31(2):338-43. PubMed ID: 9462577
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical experience with primary percutaneous transluminal coronary angioplasty compared with alteplase (recombinant tissue-type plasminogen activator) in patients with acute myocardial infarction: a report from the Second National Registry of Myocardial Infarction (NRMI-2).
    Tiefenbrunn AJ; Chandra NC; French WJ; Gore JM; Rogers WJ
    J Am Coll Cardiol; 1998 May; 31(6):1240-5. PubMed ID: 9581714
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized trial comparing primary angioplasty with a strategy of short-acting thrombolysis and immediate planned rescue angioplasty in acute myocardial infarction: the PACT trial. PACT investigators. Plasminogen-activator Angioplasty Compatibility Trial.
    Ross AM; Coyne KS; Reiner JS; Greenhouse SW; Fink C; Frey A; Moreyra E; Traboulsi M; Racine N; Riba AL; Thompson MA; Rohrbeck S; Lundergan CF
    J Am Coll Cardiol; 1999 Dec; 34(7):1954-62. PubMed ID: 10588209
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical experience with intracoronary tissue plasminogen activator: results of a multicenter registry. Intracoronary t-PA Registry Investigators.
    Cathet Cardiovasc Diagn; 1995 Mar; 34(3):196-201. PubMed ID: 7497484
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative thrombolytic properties of tissue-type plasminogen activator (t-PA), single-chain urokinase-type plasminogen activator (u-PA) and K1K2Pu (a t-PA/u-PA chimera) in a combined arterial and venous thrombosis model in the dog.
    Lu HR; Wu Z; Pauwels P; Lijnen HR; Collen D
    J Am Coll Cardiol; 1992 May; 19(6):1350-9. PubMed ID: 1342779
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A clinical trial comparing primary coronary angioplasty with tissue plasminogen activator for acute myocardial infarction.
    Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes (GUSTO IIb) Angioplasty Substudy Investigators
    N Engl J Med; 1997 Jun; 336(23):1621-8. PubMed ID: 9173270
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety of adjunctive intracoronary thrombolytic therapy during complex percutaneous coronary intervention: initial experience with intracoronary tenecteplase.
    Kelly RV; Crouch E; Krumnacher H; Cohen MG; Stouffer GA
    Catheter Cardiovasc Interv; 2005 Nov; 66(3):327-32. PubMed ID: 16208711
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intravenous thrombolytic therapy with a combination of single-chain urokinase-type plasminogen activator and recombinant tissue-type plasminogen activator in acute myocardial infarction.
    Bode C; Schuler G; Nordt T; Schönermark S; Baumann H; Richardt G; Dietz R; Gurewich V; Kübler W
    Circulation; 1990 Mar; 81(3):907-13. PubMed ID: 2106403
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sixty-minute alteplase protocol: a new accelerated recombinant tissue-type plasminogen activator regimen for thrombolysis in acute myocardial infarction.
    Gulba DC; Tanswell P; Dechend R; Sosada M; Weis A; Waigand J; Uhlich F; Hauck S; Jost S; Rafflenbeul W; Lichtlen PR; Dietz R
    J Am Coll Cardiol; 1997 Dec; 30(7):1611-7. PubMed ID: 9385884
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sequential combination thrombolytic therapy for acute myocardial infarction: results of the Pro-Urokinase and t-PA Enhancement of Thrombolysis (PATENT) Trial.
    Zarich SW; Kowalchuk GJ; Weaver WD; Loscalzo J; Sassower M; Manzo K; Byrnes C; Muller JE; Gurewich V
    J Am Coll Cardiol; 1995 Aug; 26(2):374-9. PubMed ID: 7608437
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New developments in thrombolytic therapy.
    Collen D; Gold HK
    Adv Exp Med Biol; 1990; 281():333-54. PubMed ID: 2129372
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination thrombolytic therapy: a comparison of simultaneous and sequential regimens of tissue plasminogen activator and urokinase.
    Morris JA; Muller DW; Topol EJ
    Am Heart J; 1991 Aug; 122(2):375-80. PubMed ID: 1907086
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tissue-type plasminogen activator: intracoronary applications.
    Tiefenbrunn AJ
    Cathet Cardiovasc Diagn; 1990 Feb; 19(2):108-15. PubMed ID: 2106393
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of thrombolytic therapy and primary coronary angioplasty with liberal stenting for inferior myocardial infarction with precordial ST-segment depression: immediate and long-term results of a randomized study.
    Ribichini F; Steffenino G; Dellavalle A; Ferrero V; Vado A; Feola M; Uslenghi E
    J Am Coll Cardiol; 1998 Nov; 32(6):1687-94. PubMed ID: 9822097
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Successful revascularization of coronary artery occluded by massive intracoronary thrombi with alteplase and percutaneous coronary intervention.
    Kim JS; Kim JH; Jang HH; Lee YW; Song SG; Park JH; Chun KJ
    J Atheroscler Thromb; 2010 Jul; 17(7):768-70. PubMed ID: 20467185
    [TBL] [Abstract][Full Text] [Related]  

  • 18. More rapid, complete, and stable coronary thrombolysis with bolus administration of reteplase compared with alteplase infusion in acute myocardial infarction. RAPID Investigators.
    Smalling RW; Bode C; Kalbfleisch J; Sen S; Limbourg P; Forycki F; Habib G; Feldman R; Hohnloser S; Seals A
    Circulation; 1995 Jun; 91(11):2725-32. PubMed ID: 7758177
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Coronary arterial thrombolysis with low-dose synergistic combinations of recombinant tissue-type plasminogen activator (rt-PA) and recombinant single-chain urokinase-type plasminogen activator (rscu-PA) for acute myocardial infarction.
    Collen D; Van de Werf F
    Am J Cardiol; 1987 Sep; 60(7):431-4. PubMed ID: 3115077
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low incidence of hemorrhagic infarction following coronary reperfusion with nasaruplase in a canine model of acute myocardial infarction. Comparison with recombinant t-PA.
    Kido H; Hayashi K; Uchida T; Watanabe M
    Jpn Heart J; 1995 Jan; 36(1):61-79. PubMed ID: 7760515
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.